Wakefit Innovations

Wakefit Innovations IPO: After receiving 2.52 times oversubscription in its bidding rounds, the Wakefit Innovations public issue is set to hit Dalal Street on Monday, 15 December 2025. Here's what GMP experts signal about the share debut.

After receiving a moderate response during the three-day subscription period, the shares of Wakefit Solutions are trading at a premium of ₹ 7, as per Investorgain.

Upcoming IPOs: Meanwhile, Wakefit Innovations IPO, Corona Remedies IPO, Nephrocare Health IPO and others will make their stock market debut in the upcoming week.

Wakefit Innovations IPO has finalized its allotment process, with shares set to debut on December 15 on BSE and NSE. The IPO saw a 2.52 times subscription, and the grey market indicates a steady start at ₹ 195 per share.

Wakefit Innovations IPO attracted significant investor interest with allotment on December 11, 2025. Shares will list on BSE and NSE on December 15, following a successful subscription. Investors can check allotment status online, while the company raised ₹ 1,288.89 crore through the issue.

Wakefit's IPO, launched on December 10, was oversubscribed 2.52 times, driven by strong retail interest. The company reported ₹ 724 crore in revenue and ₹ 35.5 crore profit for the six months ending September 2025, with promoter shareholding set to drop to 37%.

The primary market is active with six IPOs, including notable ones like Corona Remedies and Wakefit Innovations. Meesho, Aequs, and Vidya Wires made successful debuts. Nephrocare and Park Medi World are set to launch, while grey market premiums show varied trends for existing IPOs.

Wakefit Innovations IPO GMP today: According to market observers, shares of the company are available at a premium of ₹ 36 in the grey market today